RANCHO CUCAMONGA, Calif. , May 14, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Chloride injection 10% in the 10 mL Luer-Jet
RANCHO CUCAMONGA, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m.
Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 RANCHO CUCAMONGA, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2018 .
RANCHO CUCAMONGA, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018 , after the market closes on Wednesday, May 9, 2018 , and will hold a conference call to
RANCHO CUCAMONGA, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters , CFO will be presenting at the Needham‘s 17 th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern Time in New York, NY .
RANCHO CUCAMONGA, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on March 20, 2018 , the United States Court for the District of Massachusetts (the “District Court”) entered final judgment in favor of Amphastar in a lawsuit brought by
Reports Net Revenues of $60.4 Million for the Three Months Ended December 31, 2017 RANCHO CUCAMONGA, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months and fiscal year ended December
RANCHO CUCAMONGA, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2017 ended December 31, 2017 , after the market closes on Monday, March 12, 2018 , and will hold a conference call to
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Sodium Nitroprusside Injection 25mg/mL, 2mL single
RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectable Suspension, USP,